These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 24334854)

  • 1. Cost analysis of an intravenous to subcutaneous epoetin α conversion.
    Wazny LD; Raymond CB; Sood AR; Eng A; Verrelli M
    Am J Nephrol; 2013; 38(6):496-500. PubMed ID: 24334854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced drug costs from switching hemodialysis patients from epoetin alfa in multidose vials to pre-filled syringes.
    Wazny LD; Raymond CB; Do MK; Skwarchuk DE
    CANNT J; 2009; 19(3):39-41. PubMed ID: 19899498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
    Pizzarelli F; David S; Sala P; Icardi A; Casani A
    Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What is the practical conversion dose when changing from epoetin alfa to darbepoetin outside of clinical trials?
    Roger SD; Cooper B
    Nephrology (Carlton); 2004 Aug; 9(4):223-8. PubMed ID: 15363054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost should be the principal determinant of choice of erythropoiesis-stimulating agent in chronic haemodialysis patients.
    Courtney AE; McNamee PT; Maxwell AP
    Nephron Clin Pract; 2007; 107(1):c14-9. PubMed ID: 17664890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous versus subcutaneous dosing of epoetin alfa in hemodialysis patients.
    Paganini EP; Eschbach JW; Lazarus JM; Van Stone JC; Gimenez LF; Graber SE; Egrie JC; Okamoto DM; Goodkin DA
    Am J Kidney Dis; 1995 Aug; 26(2):331-40. PubMed ID: 7645538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
    Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term intravenous epoetin-alpha / darbepoetin-alpha ratio in iron-replete hemodialysis patients.
    Icardi A; Sacco P; Salvatore F; Romano U
    J Nephrol; 2007; 20(1):73-9. PubMed ID: 17347977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Darbepoetin alpha in lower-than-equimolar doses maintains haemoglobin levels in stable haemodialysis patients converting from epoetin alpha/beta.
    Bock HA; Hirt-Minkowski P; Brünisholz M; Keusch G; Rey S; von Albertini B;
    Nephrol Dial Transplant; 2008 Jan; 23(1):301-8. PubMed ID: 17890745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluctuations in haemoglobin levels in haemodialysis, pre-dialysis and peritoneal dialysis patients receiving epoetin alpha or darbepoetin alpha.
    Walker R; Pussell BA;
    Nephrology (Carlton); 2009 Oct; 14(7):689-95. PubMed ID: 19796029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients.
    Besarab A; Reyes CM; Hornberger J
    Am J Kidney Dis; 2002 Sep; 40(3):439-46. PubMed ID: 12200793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients.
    Kaufman JS; Reda DJ; Fye CL; Goldfarb DS; Henderson WG; Kleinman JG; Vaamonde CA
    N Engl J Med; 1998 Aug; 339(9):578-83. PubMed ID: 9718376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Change of EPO treatment from subcutaneous epoetin to intravenous epoetin or darbepoetin alpha].
    Molina M; García Hernández MA; Navarro MJ; De Gracia MC; Ortuño T
    Nefrologia; 2004; 24(6):564-71. PubMed ID: 15683029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A change from subcutaneous to intravenous erythropoietin increases the cost of anemia therapy.
    McFarlane PA; Hillmer MP; Dacouris N
    Nephron Clin Pract; 2007; 107(3):c90-6. PubMed ID: 17890876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epoetin requirement does not depend on dialysis dose when Kt/N > 1.33 in patients on regular dialysis treatment with cellulosic membranes and adequate iron stores.
    Movilli E; Cancarini GC; Vizzardi V; Camerini C; Brunori G; Cassamali S; Maiorca R
    J Nephrol; 2003; 16(4):546-51. PubMed ID: 14696757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing epoetin therapy in end-stage renal disease: the case for subcutaneous administration.
    Besarab A
    Am J Kidney Dis; 1993 Aug; 22(2 Suppl 1):13-22. PubMed ID: 8352267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose requirements among hemodialysis patients treated with darbepoetin-alpha or epoetin-beta.
    Prata MM; Dos Santos JP; Hegbrant J; Schmid CH; Pereira BJ; Wald R
    Nephron Clin Pract; 2007; 107(2):c50-5. PubMed ID: 17713351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epoetin theta: efficacy and safety of subcutaneous administration in anemic pre-dialysis patients in the maintenance phase in comparison to epoetin beta.
    Gertz B; Kes P; Essaian A; Bias P; Buchner A; Zellner D
    Curr Med Res Opin; 2012 Jul; 28(7):1101-10. PubMed ID: 22533679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
    Smith WB; Dowell JA; Pratt RD
    Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes associated with conversion from epoetin alfa to darbepoetin alfa in hospitalized hemodialysis patients.
    Sarac E; Chikyarappa A; Sabol B; Gemmel D; Globe D; Barlev A; Audhya P
    Am J Nephrol; 2006; 26(6):571-8. PubMed ID: 17170523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.